Skip to main content
. 2019 Nov 20;14(11):e0218299. doi: 10.1371/journal.pone.0218299

Table 2. Drug resistance among 2269 patients with MDR-TB and XDR-TB.

Drug Resistant MDR-TB XDR-TB p-value
n/N* (%) n/N* (%) n/N* (%)
First-line drugs
Isoniazid 2269/2269 (100.0)
Rifampicin 2269/2269 (100.0)
Ethambutol 862/2169 (39.7) 767/2031 (37.8) 95/138(68,8) <0.001
Pyrazinamide 703/1008 (69.7) 659/958 (68.8) 44/50 (88) 0.004
Streptomycin 949/2160 (43.9) 858/2022 (42.4) 91/138 (65.9) <0.001
Second-line drugs
Ethionamide 303/705 (43.0) 290/679 (41.7) 13/26 (50.0) 0.461
Amikacin 125/503 (24.8) 13/366 (3.6) 112/137 (81.8) <0.001
Kanamycin 82/383 (21.4) 4/280 (1.4) 78/103 (75.7) <0.001
Capreomycin 82/382 (21.5) 4/280 (1.4) 78/102 (76.5) <0.001
Ofloxacin 372/512 (46.9) 99/372 (26.6) 140/140 (100.0) <0.001
Ciprofloxacin 5/10 (50.0) 5/9 (55.6) 0/1 (0.0) 0.292
Moxifloxacin 13/20 (0.0) 8/14 (57.1) 5/6 (83.3) 0.260
Levofloxacin 4/9 (44.4) 2/6 (33.3) 2/3 (66.7) 0.343

MDR-TB = multidrug-resistant TB.

n/N* = number of resistance patients/total of tested patients.

Comparison between MDR/XDR-TB.